- Posted May 6, 2014 by
This iReport is part of an assignment:
- Consumers Increasingly Becoming Concerned with Food Packaging Safety
- Seniors’ Narcotics Use Under Medicare is a Growing Concern – Report
- Growing Global Population Driving Force Behind Food Industry Mergers
- Pacific Shore Holdings, Inc. Aims to Become a Billion Company Within 5 Years in Green Scene Products Arena
- 52% More Restaurants to Offer Gluten-Free Dishes in 2014 – survey
New Drug Addiction Treatment to be Offered in Georgia
BioCorRx (BICX, http://finance.yahoo.com/q?s=BICX), said in a news release it clinched a distribution agreement for Atlanta, Georgia with Dr. George Fallieras.
The new clinic will be located at 5569 Peachtree Dunwoody Rd. Ste. 280 Atlanta, GA 30342.
The move is expected to benefit patients struggling with opioid addiction.
BioCorRx’s Start Fresh Program (http://www.startfreshprogram.com/) is a new approach in treating drug addiction. It utilizes a naltrexone implant to curb appetite for drugs, which is then complemented by a life coaching program.
A 2013 report shared by non-profit organization Trust for America’s Health said Georgia has the 36th highest drug overdose mortality rate in the country. Almost 11 (10.7) of 100,000 people in the state have died from drug overdose. The number has tripled since 1999 when the rate was just at 3.5 per 100,000 people. This is high compared to other states.
Many of the deaths were attributed to prescription drugs.
Fallieras has long been working with BioCorRx as medical director of Start Fresh Recovery. He has also appeared in the television show The Doctors where he helped an alcoholic address his addiction through BioCorRx’s program.
"We are pleased that Dr. Fallieras has seen a tremendous amount of success at his other clinics affording him the opportunity to expand the national footprint of The Start Fresh Program,” BioCorRx CEO Kent Emry said in the news release.
In addition to the rising prevalence of drug overdose incidents in Georgia, the clinic is strategically located in the Atlanta Metropolitan area since it is the second largest in the Southeast, with an estimated population of 6.1 million people.
"Bringing the Start Fresh Program to this highly populated metropolitan area will positively impact many families in the Southeast while creating a broader revenue stream for BioCorRx, Inc. The Start Fresh brand has gained significant momentum in recent months, and this distribution agreement fits in nicely with our expansion plans across the US. Atlanta is a major US hub making it more convenient for people that want access to our program in that heavily populated region of the country," Emry added.
Naltrexone is a dopamine antagonist, which blocks part of the brain that creates euphoric feelings when a person takes alcohol or addictive drugs. It has long been used in heroin treatment clinics and was approved for treatment of alcohol and opioid addiction by the Food and Drug Administration.
It is often taken orally in tablet form, which has become a daily challenge for recovering addicts since relapse happens quickly when they forget or resist taking the medication.
BioCorRx’s Start Fresh Program, on the other hand, involves the insertion of a time-release naltrexone pellet in the lower abdomen part of the body. This has been proven to be more effective since it allows the patient to receive naltrexone in small doses for at least six months, without the need for additional or regular procedures. The implant could last in the body for up to one year.
During this time, the patient will undergo life coaching sessions to address his psycho-social problems that led to the addiction and help him create future plans for an addiction-free life.